Y
HN Search
Hacker News Search
new
|
comments
|
top
|
jobs
IntFee588
searching PlanetScale…
1.
▲
2.
▲
3.
▲
4.
▲
5.
▲
6.
▲
11 ms
·
31.
▲
by
IntFee588
6y ago
> just cherrypicking some niche area of use case just for the sake of differentiation, yet somehow it's worth billions of dollars in market cap. If only there was a company that financed such ventures.
32.
▲
by
IntFee588
6y ago
> if a stock market crash triggered by this is realistic Honestly, I don't think it is and there would be more media attention if it was. The firms that are shorting GME only have something like $50 billion AUM. Lehman Bros was arou
33.
▲
by
IntFee588
6y ago
Besides the huge push on dogecoin, which is big for onboarding people into crypto (yes, I know DOGE isn't DeFi), the bottlenecking of orders by brokerages undermines people's faith in the fairness of traditional securities and the
34.
▲
by
IntFee588
6y ago
I know this forum is capitalist to the core, but there is a lack of appreciation for this moment and an undue air of cynicism. This whole situation breaks a ton of fundamental assumptions about how markets work and will change hedging strat
35.
▲
by
IntFee588
6y ago
Haha I see that now, I've been on forums and reddit too long.
36.
▲
by
IntFee588
6y ago
> Levinthal's paradox What I was getting at here is that the answer to the question "does every protein have a default native conformation" is "yes."
37.
▲
by
IntFee588
6y ago
[Levinthal's paradox]( https://en.wikipedia.org/wiki/Levinthal's_paradox) was the thought experiment that "proved" that protein folding is non-random. This is currently the dominant attitude in the f
38.
▲
by
IntFee588
6y ago
When the intern learns figma.
39.
▲
by
IntFee588
6y ago
In general I agree, genetic and even epigenetic testing tends to identify problems at a point where gene therapy is no longer an option, so why bother? But if you can take tissue samples, we're getting to the point were we can detect c
40.
▲
by
IntFee588
6y ago
Overall, this is a fantastic article that touches on a lot of the issues in the biotech. Laypeople hear the term "biotech" and think of bionics, but most firms operate doing wet-lab work or synthesizing reagents/kits. The aca